Yi Wang

Publications (3)9.18 Total impact

• Article: Antiplatelet effects of qishen yiqi dropping pill in platelets aggregation in hyperlipidemic rabbits.

  Yi Wang, Jie Wang, Liping Guo, Xiumei Gao
  [show abstract] [hide abstract]
  ABSTRACT: We investigated the effects of Qishen Yiqi Dropping Pill (QSYQ) on platelets aggregation and its possible mechanisms. Hyperlipidemic model in rabbits was produced by a high fat/cholesterol diet for 6 weeks, the therapeutic effect of QSYQ with 2.0 g/kg, 1.0 g/kg, and 0.5 g/kg was observed. Fourteen days after drug treatment, platelet aggregation induced by adenosine diphosphate (ADP), arachidonic acid (AA), and collagen (COLL) was significantly reduced in rabbits of model group. Moreover, β-thromboglobulin (β-TG) level decreased obviously but no significant change in P-selectin and platelet factor 4 (PF4) level, while QSYQ significantly decreased the ratio of thromboxane B2 (TXB(2)) to 6-keto-prostaglandin F(1α) (6-Keto-PGF(1α)) and increased cyclic adenosine monophosphate (cAMP) level in rabbits. In summary, QSYQ can improve platelets aggregation and inhibit the over-release of β-TG in hyperlipidemic rabbits; and the increased cAMP level may be involved in this process. These results suggest that the antiplatelet aggregation effect of QSYQ may be due to its ability to increase cAMP level for improving cAMP metabolism.
  Evidence-based Complementary and Alternative Medicine 01/2012; 2012:205451. · 4.77 Impact Factor
• Article: Astragalosides rescue both cardiac function and sarcoplasmic reticulum Ca²⁺ transport in rats with chronic heart failure.

  Yi Wang, Yansu Ji, Yongfa Xing, Xiang Li, Xiumei Gao
  [show abstract] [hide abstract]
  ABSTRACT: The study investigated the beneficial effects of astragalosides (AS) on cardiac performance in rats with chronic heart failure. Chronic heart failure was produced by left anterior descending coronary artery ligation, and the therapeutic efficacy of astragalosides at 10, 20 and 40 mg/kg was evaluated. Five weeks after the operation, cardiac function was deficient and sarcoplasmic reticulum Ca²⁺-ATPase (SERCA) activity was significantly reduced. Moreover, SERCA mRNA decreased, while expression of the SERCA down-regulator phospholamban (PLB) was significantly increased. Phosphorylated phospholamban (P-PLB), the form that does not inhibit SERCA, was also reduced by chronic heart failure. Treatment with AS improved left ventricle function and cardiac structure, reversed the depression of SERCA activity, and increased P-PLB. These results suggest that the cardioprotective effect of AS may be due to the increase in P-PLB protein, which disinhibits SERCA activity. Rescue of sarcoplasmic reticulum Ca²⁺ cycling by astragalosides could normalize excitation-contraction coupling and improve overall cardiac function.
  Phytotherapy Research 06/2011; 26(2):231-8. · 2.09 Impact Factor
• Article: Differential cardioprotective effects of salvianolic acid and tanshinone on acute myocardial infarction are mediated by unique signaling pathways.

  Xiaoying Wang, Yi Wang, Min Jiang, Yan Zhu, Limin Hu, Guanwei Fan, Yu Wang, Xiaojia Li, Xiumei Gao
  [show abstract] [hide abstract]
  ABSTRACT: Salvianolic acid (SAL) and tanshinone (TAN) are major hydrophilic and lipophilic compounds, respectively, from one herbal medicine, Danshen, which has been widely and successfully used for treating cardiovascular diseases in Asian countries. Because few studies have reported different molecular mechanisms between the different compounds in same herb, we investigate if separate molecular pathways are involved in cardioprotective effect by different active components of Danshen. We used an acute myocardial infarction (MI) model to compare the cardioprotective effects of SAL and TAN in rats. Both infarct size and echocardiographic response were evaluated at 3, 7, 14 and 28 days after surgery. Genes involved in ischemic injury and in responses to SAL or TAN treatment in ischemic hearts were identified by microarray analysis and verified by quantitative real-time RT-PCR. Results showed that both SAL and TAN delay the development of ischemia by decreasing infarct size and improving systolic function post MI. Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis indicated different kinetics and gene expression profiles by SAL and TAN. SAL acts in a later period after ischemia, and its effect is probably mediated by downregulation of genes involved in oxidative stress, certain G-protein coupled receptor activities and apoptosis. On the other hand, TAN acts relatively early after ischemic injury and its effect is at least in part mediated by inhibition of intracellular calcium, cell adhesion and alternative complement pathway. Strikingly, we found that TAN, a recently identified member of selective estrogen receptor modifier (SERM), indeed regulates genes known to be involved in estrogen metabolism post MI. Although both SAL and TAN contribute to the cardioprotective effect of Danshen, there are significant mechanistic and temporal differences between the two: TAN acts at an early stage after ischemic injury mainly by inhibition of intracellular calcium and cell adhesion pathways whereas SAL acts mainly by down-regulating apoptosis.
  Journal of ethnopharmacology 06/2011; 135(3):662-71. · 2.32 Impact Factor